BridgeMD
New treatment option for Type2 Diabetes Mellitus
Official title SnapDandCGMinType2Diabetes
ClinicalTrials.gov ID: NCT07533604
What this study is testing
- What it's testing
- Study Title: The Effectiveness of an AI-powered Thai food analysis (SnapD) and Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes and Overweight or Obesity: A Randomized Controlled Pilot Study Rationale: Effective dietary management is the cornerstone of treating Type 2 Diabetes (T2DM) and obesity. However, traditional manual food logging is often inaccurate and burdensome.
- Time commitment: about 8 weeks
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Aged 18 to 65 years, male or female at birth
- Diagnosed with type 2 Diabetes Mellitus with overweight or obesity (BMI\>23 kg/m²)
- Hemoglobin A1c (HbA1c) 6.5-9% measured within 3 months prior to the screening date
- Willing to maintain their current antidiabetic medication regimen without dose adjustment for the entire 8-week study duration
- Must possess an internet-enabled devices e.g. smartphone, tablet compatible with the SnapD application
You likely can't join if
- Currently pregnant, plan pregnancy or breastfeeding during the 8-week study period
- Current participation in another treatment clinical trial
- Current use of insulin or incretin-based therapies (e.g., GLP-1 Receptor Agonists, GIP/GLP-1 Receptor Agonists)
- Presence of severe hearing or visual impairment that, in the investigator's judgment, would preclude the participant from safely and effectively...
- known contraindication to CGM usage e.g., a history of severe hypersensitivity to the device's materials or adhesive, planing to go on CT-contrasted...
See the full eligibility criteria
- Aged 18 to 65 years, male or female at birth
- Diagnosed with type 2 Diabetes Mellitus with overweight or obesity (BMI\>23 kg/m²)
- Hemoglobin A1c (HbA1c) 6.5-9% measured within 3 months prior to the screening date
- Willing to maintain their current antidiabetic medication regimen without dose adjustment for the entire 8-week study duration
- Must possess an internet-enabled devices e.g. smartphone, tablet compatible with the SnapD application
- Able and willing to adhere intervention, including using snapD and CGM
- Currently pregnant, plan pregnancy or breastfeeding during the 8-week study period
- Current participation in another treatment clinical trial
- Current use of insulin or incretin-based therapies (e.g., GLP-1 Receptor Agonists, GIP/GLP-1 Receptor Agonists)
- Presence of severe hearing or visual impairment that, in the investigator's judgment, would preclude the participant from safely and effectively using the SnapD application or the CGM device
- known contraindication to CGM usage e.g., a history of severe hypersensitivity to the device's materials or adhesive, planing to go on CT-contrasted imaging etc.
The study team makes the final eligibility decision.
Where it's taking place
- Bangkok, Bangkok, Thailand
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 8 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bangkok, Bangkok, Thailand. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.